← Back

Wire · opportunities

FDA nod to first treatment for neurological symptoms of Type 3 Gaucher disease

Published

22 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at indianpharmapost.com →

◆ Verified

Fusion42 · 22 November 2026 · Fusion42 review

The US FDA approved Infilbray (venglustat), the first drug targeting neurological symptoms of Type 3 Gaucher disease, designed to cross the blood-brain barrier and reduce harmful substance buildup in the brain.

This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 18 Nov 2026 and 22 Nov 2026.

◆ ◆ The Wire takeaway

Neurological symptoms of Type 3 Gaucher disease now have a drug treatment option, opening patient access and creating a market for therapies crossing the blood-brain barrier. You need to consider repositioning or developing treatments for rare neurological disorders with overlooked CNS involvement.

◆ Coverage

8 sources · first reported 18 Nov 2026 · latest 22 Nov 2026

◆ Related on Wire

◆ Topics

BiotechFDA-approvalrare-diseaseneurological-treatmentorphan-drugvenglustat